Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy.

Investigational new drugs - 1 Dec 2022

Ogusu Shinsuke, Ariyasu Ryo, Akita Takahiro, Kiritani Ayu, Tsugitomi Ryosuke, Amino Yoshiaki, Uchibori Ken, Kitazono Satoru, Yanagitani Noriko, Nishio Makoto

Abstract excerpt

Data on the re-administration of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) after osimertinib failure in patients with T790M-positive non-small cell lung cancer (NSCLC) is limited. EGFR-TKI re-administration efficacy may vary between patients with T790M loss and those with T790M persistent with re-biopsy after osimertinib treatment. Patients who received EGFR-TKI re-administration...

Topics

Join the communities discussing this publication.

Aniline Compounds
Biopsy
Carcinoma, Non-Small-Cell Lung
ErbB Receptors
Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Protein Kinase Inhibitors

Source

Identifiers

PMID: 36152107
DOI: 10.1007/s10637-022-01301-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy.PMID 36152107Read ↗

Real-world data on efficacy and safety of osimertinib in non-small cell lung cancer patients with EGFR T790M mutation detected by first and repeat rebiopsy.Semantic proximity Read ↗

Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI.Semantic proximity Read ↗

Real-World T790M Mutation Frequency and Impact of Rebiopsy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Should We Perform Repeated Re-biopsy for the Detection of T790M Mutation?Semantic proximity Read ↗

Repeated rebiopsy for detection of EGFR T790M mutation in patients with advanced-stage lung adenocarcinoma: Associated factors and treatment outcomes of Osimertinib.Semantic proximity Read ↗

Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment.Semantic proximity Read ↗

First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study.Semantic proximity Read ↗

Empirical Osimertinib as a Second-Line Treatment Is a Viable Option Following First- and Second-Generation TKI Therapy With Unknown EGFR Status in Treated Non-Small Cell Lung Cancer: A Retrospective Study.Semantic proximity Read ↗

Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer.Semantic proximity Read ↗

Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.Semantic proximity Read ↗

Acquired EGFR C797G Mutation Detected by Liquid Biopsy as Resistance Mechanism After Treatment With Osimertinib: A Case Report.Semantic proximity Read ↗

Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.